Table 3 Differences in scores of PROMIS instrument items for PCSK9i and Statins.

From: Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial

PROMIS 10

Total

PCSK9i

Statins

P value

GPH

 Physical health

  Baseline

2.88 ± 0.85

2.93 ± 0.83

2.83 ± 0.87

0.188

  Week 12

3.29 ± 0.93

3.39 ± 0.96

3.19 ± 0.89

0.019

  Week 48

3.78 ± 1.00

3.90 ± 0.93

3.65 ± 1.05

0.007

 Physical function

  Baseline

3.15 ± 0.88

3.17 ± 0.90

3.14 ± 0.86

0.649

  Week 12

3.26 ± 1.01

3.30 ± 1.10

3.21 ± 0.91

0.339

  Week 48

3.73 ± 0.77

3.79 ± 0.77

3.67 ± 0.76

0.107

 Fatigue

  Baseline

4.08 ± 0.70

4.16 ± 0.66

4.00 ± 0.72

0.010

  Week 12

3.97 ± 0.65

4.04 ± 0.70

3.90 ± 0.58

0.015

  Week 48

4.29 ± 0.65

4.34 ± 0.64

4.25 ± 0.66

0.130

 Pain intensity

  Baseline

4.00 ± 2.82

4.05 ± 2.79

3.95 ± 2.86

0.692

  Week 12

1.55 ± 2.39

1.17 ± 1.99

1.94 ± 2.68

< 0.001

  Week 48

0.77 ± 1.03

0.80 ± 0.93

0.74 ± 1.13

0.481

 GMH

 Overall quality of life

  Baseline

2.97 ± 0.87

3.01 ± 0.86

2.94 ± 0.89

0.385

  Week 12

3.36 ± 0.91

3.46 ± 0.90

3.26 ± 0.90

0.013

  Week 48

3.84 ± 0.85

3.91 ± 0.83

3.77 ± 0.86

0.083

 Mental health

  Baseline

3.08 ± 0.80

3.12 ± 0.83

3.04 ± 0.78

0.290

  Week 12

3.63 ± 0.85

3.80 ± 0.83

3.45 ± 0.84

< 0.001

  Week 48

3.91 ± 0.95

4.01 ± 0.89

3.82 ± 0.99

0.032

 Satisfaction with social activities

  Baseline

3.10 ± 0.86

3.18 ± 0.86

3.02 ± 0.87

0.049

  Week 12

3.60 ± 1.05

3.80 ± 1.09

3.40 ± 0.97

< 0.001

  Week 48

4.06 ± 0.86

4.16 ± 0.82

3.95 ± 0.90

0.009

 Emotional problems

  Baseline

3.84 ± 0.86

3.88 ± 0.87

3.81 ± 0.86

0.406

  Week 12

4.15 ± 0.77

4.21 ± 0.77

4.09 ± 0.76

0.082

  Week 48

4.16 ± 0.98

4.15 ± 1.02

4.17 ± 0.94

0.819